Sinopharm Group Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 90,447

Employees

  • Stock Symbol
  • 01099

Stock Symbol

  • Investments
  • 14

  • Share Price
  • $2.14
  • (As of Friday Closing)

Sinopharm Group General Information

Description

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 9/F, The Center, 99 Queen's Road, Central
  • Hong Kong, 200051
  • China
+86 0852
Primary Industry
Pharmaceuticals
Stock Exchange
HKG
Corporate Office
  • 9/F, The Center, 99 Queen's Road, Central
  • Hong Kong, 200051
  • China
+86 0852

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sinopharm Group Stock Performance

As of 20-Nov-2026, Sinopharm Group’s stock price is $2.14. Its current market cap is $6.69B with 3.12B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.14 $2.16 $1.85 - $2.86 $6.69B 3.12B 5.6M $0.32

Sinopharm Group Financials Summary

As of 30-Jun-2026, Sinopharm Group has a trailing 12-month revenue of $81.7B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 16,597,232 23,078,039 23,099,863 25,194,408
Revenue 81,734,323 79,980,849 81,459,297 84,322,217
EBITDA 2,889,115 2,904,686 2,905,968 3,696,968
Net Income 1,013,694 994,963 982,471 1,279,705
Total Assets 59,524,392 55,792,190 53,811,762 54,086,116
Total Debt 11,968,311 10,141,985 10,463,711 10,408,522
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sinopharm Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sinopharm Group‘s full profile, request access.

Request a free trial

Sinopharm Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on th
Pharmaceuticals
Hong Kong, China
90,447 As of 2026

Beijing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sinopharm Group Competitors (1)

One of Sinopharm Group’s competitors is Sinovac Biotech, a Corporation company based in Beijing, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sinovac Biotech Corporation Beijing, China
You’re viewing 1 of 1 competitors. Get the full list »

Sinopharm Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sinopharm Group Investments & Acquisitions (14)

Sinopharm Group’s most recent deal was a Early Stage VC with Jinju Biomedicine. The deal was made on 19-Nov-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Jinju Biomedicine 19-Nov-2025 Early Stage VC Biotechnology
Hayat Biotech 08-Apr-2025 Joint Venture Biotechnology
Joint Venture (Elekta / Sinopharm Group) 07-Sep-2023 Joint Venture Medical Supplies
Hayat-Vax Vaccine Manufacturing (G42 / Sinopharm CNBG) 28-Mar-2021 Joint Venture Pharmaceuticals
HY Medical 16-Nov-2020 Later Stage VC Decision/Risk Analysis
You’re viewing 5 of 14 investments and acquisitions. Get the full list »

Sinopharm Group ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

15.9 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Distribution

Subindustry

of 42

Rank

Percentile

To view Sinopharm Group’s complete esg history, request access »

Sinopharm Group Exits (2)

Sinopharm Group’s most recent exit was on 01-May-2019 from GemPharmatech. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
GemPharmatech 01-May-2019 Completed
  • 2 buyers
Jienuo Medical Management Group 20-Feb-2019 Secondary Transaction - Private Completed
To view Sinopharm Group’s complete exits history, request access »

Sinopharm Group Affiliates

Subsidiaries (4)

Name Industry Location Year Founded
Sinopharm Capital Shanghai, China 2012
China National Medicines Corporation Beijing, China 1999
China National Pharmaceutical Investment Beijing, China 1964
Sinopharm Medical Equipment Beijing, China 1962

Sinopharm Group FAQs

  • When was Sinopharm Group founded?

    Sinopharm Group was founded in 2003.

  • Where is Sinopharm Group headquartered?

    Sinopharm Group is headquartered in Hong Kong, China.

  • What is the size of Sinopharm Group?

    Sinopharm Group has 90,447 total employees.

  • What industry is Sinopharm Group in?

    Sinopharm Group’s primary industry is Pharmaceuticals.

  • Is Sinopharm Group a private or public company?

    Sinopharm Group is a Public company.

  • What is Sinopharm Group’s stock symbol?

    The ticker symbol for Sinopharm Group is 01099.

  • What is the current stock price of Sinopharm Group?

    As of 20-Nov-2026 the stock price of Sinopharm Group is $2.14.

  • What is the current market cap of Sinopharm Group?

    The current market capitalization of Sinopharm Group is $6.69B.

  • What is Sinopharm Group’s current revenue?

    The trailing twelve month revenue for Sinopharm Group is $81.7B.

  • Who are Sinopharm Group’s competitors?

    Sinovac Biotech is a competitor of Sinopharm Group.

  • What is Sinopharm Group’s annual earnings per share (EPS)?

    Sinopharm Group’s EPS for 12 months was $0.32.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process